PDGF BB and Its Role in Development and Disease

PDGF-BB is one of the most versatile signaling proteins in the human body, orchestrating processes from blood vessel formation in the embryo to wound closure in the adult. It belongs to a small family of platelet-derived growth factors, but the BB form stands out because it can activate both of the known PDGF receptor types, giving it an unusually broad reach across tissues and cell types. That versatility cuts both ways: the same molecule that helps build organs during fetal development can drive fibrosis, thicken diseased arteries, and support tumor growth when its signaling goes unchecked. Understanding PDGF-BB means understanding a molecular switch that the body relies on constantly and that medicine is still learning to manipulate.

How PDGF-BB Binds and Signals

The PDGF family includes several forms, but three get the most attention: AA, AB, and BB. These are dimers, meaning each active molecule is built from two protein chains locked together. What makes PDGF-BB distinctive is its receptor flexibility. There are two PDGF receptor subtypes, called alpha and beta. PDGF-AA binds only the alpha receptor, while PDGF-BB binds both alpha and beta with high affinity, in the low-nanomolar range.¹ Detailed binding studies using cells engineered to carry each receptor subtype confirmed that PDGF-BB binds the alpha receptor at roughly 0.4 nM affinity, which, while somewhat lower than the AA form’s binding to that same receptor, is still more than strong enough to trigger a response at the concentrations found in living tissue.²

When PDGF-BB docks onto its receptors, it physically pulls two receptor molecules together. That dimerization triggers a cascade of internal signals. Two major downstream pathways are the PI3K/AKT pathway and the MAPK (also called ERK) pathway. Both drive cell survival, growth, and movement. Studies in pulmonary vein tissue, for example, have shown that PDGF-BB regulates vascular tone through prostaglandin production, calcium signaling, and activation of both MAPK and PI3K/AKT/mTOR cascades.³ There is also evidence that PDGF-BB can activate MAPK through routes that do not depend on the beta receptor’s own tyrosine phosphorylation, hinting at backup signaling circuits that make this growth factor’s effects harder to switch off than researchers once assumed.⁴

Building Organs Before Birth

PDGF-BB’s most dramatic roles play out during embryonic development, where it helps assemble the structural scaffolding of several organs. The best-studied example is blood vessel maturation. New blood vessels start as simple tubes lined by endothelial cells, but they need a second cell type, called pericytes, to wrap around them and provide stability. Endothelial cells secrete PDGF-BB as a recruitment signal. When pericyte recruitment is disrupted, vessels become leaky, overly wide, and prone to hemorrhage. Work in quail embryos showed that blocking PDGF-BB signaling alongside another growth factor led to exactly that: fewer pericytes reached the vessel tubes, basement membrane formation dropped, and vascular hemorrhage followed.⁵

The kidneys tell a similar story. Inside each kidney glomerulus, specialized cells called mesangial cells provide structural support for the filtration apparatus. Mice engineered to lack either PDGF-B or its beta receptor fail to develop mesangial cells properly. Some early precursor cells appear, but the mesangium never matures.⁶ The signal is not needed to specify the mesangial cell lineage in the first place; it is needed to expand and maintain those cells once they exist. Without it, the kidney’s filtration units are structurally defective.

PDGF-BB also reaches the developing brain. Neural stem and progenitor cells express the beta receptor, and studies using knockout models have found that removing the receptor reduces the self-renewal capacity and multipotency of these cells, with the effects being especially pronounced in the neonatal period.⁷ The implication is that PDGF-BB signaling helps keep the pool of brain progenitor cells large and versatile during the critical early window when most neural architecture is being laid down.

Wound Healing and Tissue Repair

After birth, PDGF-BB shifts from organ builder to tissue repairman. When skin is broken, platelets arrive first. They aggregate at the wound site, degranulate, and release a cocktail of growth factors, including PDGF-BB.⁸ From that point, PDGF-BB serves two functions that are easy to conflate but actually distinct: it draws cells into the wound bed, and it tells them what to do once they arrive.

The drawing-in part is especially clear for fibroblasts, the cells responsible for laying down new connective tissue. Experiments with human dermal fibroblasts found that PDGF-BB is the dominant motility factor in serum for these cells. Blocking it with neutralizing antibodies completely eliminated serum-driven fibroblast migration. Collagen alone can get fibroblasts moving at a basic level, but PDGF-BB adds directionality and speed.⁹ Beyond migration, beta-receptor signaling drives fibroblast proliferation and helps recruit pericytes to the new blood vessels forming inside the wound. Blocking the beta receptor in wound models potently inhibited both fibroblast and pericyte recruitment during the early healing phases.¹⁰

When Healing Goes Too Far: Fibrotic Disease

Fibrosis is, in a sense, wound healing that never stops. The same PDGF-BB signals that recruit fibroblasts and pericytes to a cut can, in a chronically injured organ, drive the relentless accumulation of scar tissue. PDGF isoforms are recognized as major stimulators of myofibroblast replication, survival, and migration during fibrotic disease, and the receptors themselves get upregulated during fibrogenesis, amplifying the response.¹¹

The liver is where this problem has been studied most intensively. Chronic liver injury from alcohol, viral hepatitis, or toxins activates hepatic stellate cells, the resident fibroblast-like cells of the liver. PDGF-BB is a primary driver of that activation: it pushes stellate cells to migrate, proliferate, and deposit collagen.¹² The process involves crosstalk between PDGF-BB and another potent fibrogenic signal, TGF-beta. Damaged liver cells release both factors, and neutralizing antibodies against PDGF-BB and TGF-beta together can block stellate cell activation triggered by conditioned media from injured hepatocytes.¹³

Because the beta receptor is such a reliable marker of active liver fibrosis, it has become a therapeutic target. Compounds like salvianolic acid B have been shown to bind the beta receptor directly, suppressing the activation, migration, and proliferation of stellate cells and damping the PDGF-BB signaling cascade.¹⁴ Propranolol, a common beta-blocker already used in liver disease for other reasons, has also shown antifibrotic effects by inhibiting PDGF-BB-induced beta-receptor phosphorylation and the downstream Akt pathway.¹⁵ These are still largely experimental or early-stage findings, but they illustrate how central PDGF-BB signaling is to the fibrotic process.

Cardiovascular Disease and Vascular Remodeling

Arteries are lined with smooth muscle cells that normally sit in a quiet, contractile state, keeping vessels toned and responsive. In diseases like atherosclerosis and pulmonary arterial hypertension, these cells switch to an active, proliferative mode. PDGF-BB is one of the main triggers for that switch. In response to PDGF-BB, vascular smooth muscle cells transform from their normal spindle shape into a rounded, protein-churning phenotype that multiplies, migrates, and contributes to vessel wall thickening.¹⁶

In the pulmonary arteries specifically, PDGF-BB has been proposed as a key mediator of pulmonary arterial hypertension, a life-threatening condition in which the blood vessels serving the lungs become progressively narrower. PDGF-BB drives the proliferation and migration of pulmonary artery smooth muscle cells while suppressing their apoptosis, leading to a net thickening of the vessel walls.¹⁷ Metabolic studies of these cells after PDGF-BB treatment show a global shift: cells move from a contractile to a synthetic state with measurable increases in viability, proliferation, and migration.¹⁸ Tyrosine kinase inhibitors such as imatinib, which block the PDGF receptor among other targets, have been explored as treatments for pulmonary arterial hypertension, though their clinical use remains limited by side effects.

PDGF-BB in Cancer

Tumors need a supportive stroma, a surrounding mesh of connective tissue, blood vessels, and immune cells, to grow. PDGF-BB helps tumors build it. In lung adenocarcinoma cells, exogenous PDGF-BB activated both the PI3K/AKT and MAPK signaling pathways, promoting cell growth, while knocking down PDGF-BB expression had the opposite effect.¹⁹

A particularly interesting mechanism involves what researchers call pericyte-fibroblast transition. Pericytes, the same cells PDGF-BB recruits to stabilize blood vessels during development, can be reprogrammed by PDGF-BB in the tumor environment. They detach from vessels and take on fibroblast-like properties, contributing to invasion and metastasis. Gain- and loss-of-function experiments confirmed that PDGF-BB signaling through the beta receptor drives this transition both in lab dishes and in living tumors. Gene expression analysis revealed that PDGF-BB-activated pericytes acquire features of mesenchymal progenitor cells, essentially becoming a source of new supportive stroma for the tumor. Blocking the beta receptor pharmacologically or genetically eliminated this transition.²⁰

Separately, PDGF receptor mutations play a central role in gastrointestinal stromal tumors, where activating mutations in either KIT or the alpha PDGF receptor drive tumor growth. Imatinib, the first targeted therapy approved for these tumors, works partly by blocking the PDGF receptor. But resistance is common: roughly two-thirds of patients who eventually progress on imatinib have tumors with secondary kinase mutations, often in the same receptor that was being targeted.²¹ Newer agents and combination strategies continue to be explored, but drug resistance mediated through non-KIT/PDGFRA pathways remains a persistent clinical problem.²²

Becaplermin and Diabetic Ulcers

The most direct therapeutic application of PDGF-BB itself, rather than drugs that block it, is in chronic wound care. Becaplermin gel is a topical formulation of recombinant human PDGF-BB approved for diabetic foot ulcers. These wounds are notoriously slow to heal because the diabetic environment impairs normal growth factor signaling and blood supply. By supplying PDGF-BB directly to the wound bed, the gel aims to restart the stalled recruitment of fibroblasts and support tissue formation.

In a pivotal phase III trial, becaplermin gel at the 100 microgram-per-gram dose increased the rate of complete wound closure by about 43% compared to placebo gel (50% vs. 35% closure), and shortened the time to closure by roughly a third.²³ In open-label follow-up evaluations, just over half of patients achieved complete healing, with a mean time to closure of about two months, though recurrence within six months was still around 21%.²⁴ A systematic review and meta-analysis of available trials confirmed that recombinant PDGF-BB is effective for diabetic lower-extremity ulcers as a class.²⁵ It is not a miracle cure by any measure, but in a disease space where few pharmacologically active treatments exist, becaplermin remains a notable success story for growth factor therapy.

Bone Formation and Regeneration

PDGF-BB’s ability to recruit pericytes and stimulate cell proliferation extends to bone repair. After a fracture or bone graft, new bone formation depends on a tightly coordinated sequence: blood vessels must invade the injury site, progenitor cells must migrate there, divide, and differentiate into bone-forming osteoblasts. PDGF-BB appears to act as a connector between these steps. It mobilizes pericytes from their locations on existing blood vessels, stimulates their expansion, and helps organize them at the injury site, contributing both to the osteogenic lineage and to the stabilization of new blood vessels that supply the regenerating bone.²⁶ This dual role, feeding both the bone-building and the blood-supply sides of the process, helps explain why PDGF-BB has been investigated as a component of orthopedic graft materials and bone tissue engineering scaffolds.

Eye Disease and Dual-Target Strategies

Neovascular (wet) age-related macular degeneration is driven by abnormal new blood vessel growth beneath the retina. Standard treatment blocks VEGF-A, the main signal for new vessel sprouting. But PDGF-BB plays a complementary role: it recruits and maintains pericytes on those abnormal vessels, making them more resistant to VEGF-A blockade alone. In animal models of subretinal neovascularization, blocking PDGF-BB alone had modest effects, but combining anti-PDGF-BB and anti-VEGF-A agents produced significantly greater vessel suppression than either alone across multiple models of disease severity.²⁷

This preclinical rationale led to a clinical trial testing E10030, an anti-PDGF aptamer (marketed as Fovista), combined with standard anti-VEGF therapy. In a phase IIb trial, the combination produced a mean visual acuity gain about four letters greater than anti-VEGF monotherapy at 24 weeks, meeting its prespecified primary endpoint.²⁸ The enthusiasm was significant, but later-stage trials did not replicate that advantage convincingly, and the dual-targeting approach has not become standard of care. Still, the biology underlying the attempt, that PDGF-BB-maintained pericytes armor new vessels against VEGF blockade, remains a valid concept and continues to inform combination strategies in ophthalmology and oncology.

Evolutionary Divergence of PDGF Receptor Signaling

An often-overlooked aspect of PDGF biology is that the two receptor subtypes, alpha and beta, have diverged in what they do when they signal. Experiments using chimeric and mutant receptors in mouse embryos revealed that a modified alpha receptor could rescue some developmental defects (neural crest and blood vessel formation) seen in animals lacking the normal alpha receptor, but not others (skeletal or extraembryonic defects). The rescues mapped roughly to which downstream pathways the modified receptor could still activate: MAPK signaling was restored to near-normal, while PI3K activation was not.²⁹ A different chimeric receptor, engineered to carry signaling elements from the fibroblast growth factor receptor, failed to rescue any normal alpha-receptor functions and instead caused ectopic bone formation, a gain-of-function defect.

These findings matter because they show that the two PDGF receptors are not interchangeable signal conduits. They have specialized over evolutionary time to activate different downstream pathway combinations in different tissues. PDGF-BB, as the ligand that binds both, sits at the intersection of these divergent pathways, which helps explain why its effects are so context-dependent. In one tissue it builds vessels; in another it promotes fibrosis; in a third it drives tumor stroma formation. The molecule is the same, but the receptor mix and the cellular context determine the outcome.

The Retention Motif and Local Action

One last piece of biology worth knowing about: the PDGF A-chain has two splice variants, and the longer one contains a stretch of positively charged amino acids near its tail that acts as a retention motif, keeping the growth factor tethered to the cell surface or the surrounding extracellular matrix rather than letting it diffuse freely.³⁰ PDGF-BB, by contrast, lacks this kind of strong retention signal, which allows it to diffuse more freely through tissue and act at greater distances from the cells that produce it. This distinction between tethered and diffusible PDGF isoforms is part of what makes PDGF-BB such an effective long-range recruiter of pericytes and fibroblasts: it can establish concentration gradients that cells follow over relatively large distances, guiding them to wherever the signal originates. It also helps explain why PDGF-BB’s effects can be harder to contain in disease settings. A freely diffusing signal that stimulates cell proliferation and migration is powerful when pointed at a wound, and dangerous when pointed at nothing in particular.